The European Food Safety Authority (EFSA) has rejected health claims submitted by Belgian omega-3 supplements manufacturer, Minami Nutrition Health, purportedly linking omega-3 form EPA (eicosapentaenoic acid) and reduced risk of ADHD in children.

According to a news source, the claims suggested that “attention deficithyperactivity disorder (ADHD) could be reduced by improving the ratio between arachidonic acid (AA) and EPA in the body.” EFSA disagreed, stating “No evidence was provided by the applicant to substantiate that the AA/ EPA ratio plays a role in the development of ADHD, that the AA/EPA ratio can predict the incidence of ADHD, or that lowering the AA/EPA ratio can lower the risk of ADHD.”

The only “approved health claim for EPA in the European Union is an article 13, general function health claim for, ‘Maintenance of normal cardiac function,’” according to a news source. See, April 15, 2013.